Free Newsletter
Novartis plots $700M biotech plant
Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution and for clinical development. More than 300 people are expected to work there when it's complete in 2012.
It's Novartis' second big investment in Singapore manufacturing. The company just opened a new $180 million tabletting plant there today; it's expected to employ some 160 workers. Singapore was featured twice on our annual list of the top five regions attracting biotech business.
- check out the report from Channel News Asia
Related Articles:
Novartis injects $816.5M in vaccine plant. Report
Singapore to spend $8B on biotech R&D. Report
GSK opens $13M drug discovery lab in Singapore. Report
Singapore to spend $8B on biotech R&D. Report
GSK blueprints $190M vaccine plant for Singapore. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: